Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0085580
Disease: Essential Hypertension
Essential Hypertension 		0.300 Biomarker disease CTD_human
CUI: C1840374
Disease: Elevated systolic blood pressure
Elevated systolic blood pressure 		0.100 Biomarker phenotype HPO
CUI: C1840375
Disease: Elevated diastolic blood pressure
Elevated diastolic blood pressure 		0.100 Biomarker phenotype HPO
CUI: C1840376
Disease: Elevated mean arterial pressure
Elevated mean arterial pressure 		0.100 Biomarker phenotype HPO
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.390 Biomarker disease CTD_human Prostate cancer patients with CYP3A5*3/*3 and KLK -252A > G GG/AG genotypes had decreased OR of 0.70 with 95% CI 0.50-0.98 for high prostate-specific antigen levels at diagnosis. 18306354 2008
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus 		0.010 GeneticVariation group BEFREE Diabetes mellitus, CYP2C19*2 (rs4244285), clopidogrel resistance, and the interaction of CYP2C19*2 with CYP3A5 were all independent risk factors for the primary outcomes of clopidogrel treatment. 26961113 2016
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 AlteredExpression group BEFREE Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer. 30881507 2019
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease 		0.100 Biomarker group BEFREE CYP3A5 expressors, was significantly higher among patients with a diagnosis of hypertension than among patients without (18.3% vs 9.0%, p = 0.016). 15952872 2005
CUI: C0001430
Disease: Adenoma
Adenoma 		0.010 AlteredExpression group BEFREE CYP3A5 mRNA expression was significantly higher in adenoma in comparison to normal tissue of patients with adenoma (approximately 48%). 16281975 2005
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 GeneticVariation group BEFREE CYP3A5 genotype may affect cancer susceptibility. 16430309 2006
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 GeneticVariation group BEFREE CYP3A5 genotype may affect cancer susceptibility. 16430309 2006
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease 		0.100 GeneticVariation group BEFREE CYP3A5 genotype does not contribute importantly to BP or risk of HTN, but may influence response to calcium channel blockers in populations in which carrier status of two functional alleles is common. 17339868 2007
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.390 AlteredExpression disease BEFREE Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer. 17914095 2007
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.090 AlteredExpression disease BEFREE Cytochrome P450 3A5 is highly expressed in normal prostate cells but absent in prostate cancer. 17914095 2007
CUI: C3854222
Disease: Human immunodeficiency virus (HIV) II infection category B1
Human immunodeficiency virus (HIV) II infection category B1 		0.020 GeneticVariation disease BEFREE CYP3A5 genotype has no impact on the trough plasma concentrations of lopinavir and ritonavir in human immunodeficiency virus (HIV)-infected individuals on stable highly active antiretroviral therapy (HAART). 18288082 2008
CUI: C0020538
Disease: Hypertensive disease
Hypertensive disease 		0.100 Biomarker group BEFREE CYP3A5 and ABCB1 genes and hypertension. 19290795 2009
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. 21209234 2011
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 Biomarker group BEFREE CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone. 21209234 2011
CUI: C0020443
Disease: Hypercholesterolemia
Hypercholesterolemia 		0.040 AlteredExpression disease BEFREE CYP3A5*3C (AGT haplotype) was associated to lower basal CYP3A5 mRNA expression in HC (p<0.045), however none of the haplotype groups impacted treatment. 23501331 2013
CUI: C1096063
Disease: Drug Resistant Epilepsy
Drug Resistant Epilepsy 		0.010 GeneticVariation disease BEFREE CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescents. 23984379 2013
CUI: C3826394
Disease: Epilepsy in children
Epilepsy in children 		0.010 GeneticVariation disease BEFREE CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescents. 23984379 2013
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE CYP3A5 is a cytochrome P450 protein that functions in the liver metabolism of many carcinogens and cancer drugs. 25649767 2015
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.100 Biomarker group BEFREE CYP3A5 is a cytochrome P450 protein that functions in the liver metabolism of many carcinogens and cancer drugs. 25649767 2015
CUI: C0278678
Disease: Metastatic Renal Cell Cancer
Metastatic Renal Cell Cancer 		0.010 GeneticVariation disease BEFREE CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. 25930089 2015
CUI: C4721698
Disease: Metastatic Renal Cell Carcinoma
Metastatic Renal Cell Carcinoma 		0.010 GeneticVariation disease BEFREE CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. 25930089 2015